Common binding requirements of PPAR-α/δ/ γ pan agonists: Quantitative structure-activity relationship analysis of indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail group

Medicinal Chemistry Research

Volumn 21, Issue 6, 2012, Pages 891-907

  Paliwal, Sarvesh ^a   Yadav, Divya ^a   Yadav, Rakesh ^a   Kaushik, Vandana ^a   Paliwal, Shailendra ^a  

^a BANASTHALI UNIVERSITY   (India)

Author keywords

2D QSAR; Antidiabetic; Indanylacetic acid derivatives carrying 4 thiazolyl phenoxy tail groups; Pan agonists; TSAR

Indexed keywords

ACETIC ACID DERIVATIVE; INDANYLACETIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DIPOLE; DRUG RECEPTOR BINDING; HYDROGEN BOND; MULTIPLE LINEAR REGRESSION ANALYSIS; PARTIAL LEAST SQUARES REGRESSION; PHYSICAL CHEMISTRY; PREDICTIVE VALUE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STATISTICAL MODEL;

EID: 84861845304     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-011-9599-z     Document Type: Article

References (49)

1. Artis DR, Lin JJ, Zhang C, Wang W, Mehra U, Perreault M, Erbe D, Krupka HI, England BP, Arnold J (2009) Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci USA 106:262-267
2. Auwerx J (1999) PPAR c, the ultimate thrifty gene. Diabetologia 42: 1033-1049
3. Balfour B, Plosker GL (1999) Rosiglitazone. Drugs 57:921-930 (Pubitemid 29313203)
4. Barish GD, Narkar VA, Evans RM (2006) PPAR d: a dagger in the heart of the metabolic syndrome. J Clin Investig 116:590-597 (Pubitemid 43326863)
5. Besalu E (2007) Trends and plot methods in MLR studies. J Chem Inf Model 47:751-760 (Pubitemid 46973688)
6. Cheng CF, Chen HH, Lin H (2010) Role of PPARa and its agonist in renal diseases. PPAR Res. doi:10.1155/2010/345098
7. Cramer RD (1993) Partial Least Square (PLS): its strength and limitations. Perspect Drug Discov Des 1:269-278
8. Cronin MTD, Schultz TW (2001) Development of quantitative structure-activity relationships for the toxicity of aromatic compounds to Tetrahymena pyriformis: comparative assessment of the methodologies. Chem Res Toxicol 14:1284-1295 (Pubitemid 32911469)
9. Dalby A, Nourse JG, Hounshell WD, Gushurst AKI, Grier DL, Leland BA, Laufer J (1992) Description of several chemical structure file formats used by computer programs developed at Molecular Design Limited. J Chem Inf Comput Sci 32:244-255
10. Dessalew N (2008) QSAR study on piperidine carboxamides as antiretroviral agents: an insight into the structural basis for HIV coreceptor antagonist activity. QSAR Comb Sci 27:901-912
11. Dessalew N (2009) Investigation of the structural requirement for inhibiting HIV integrase: QSAR study. Acta Pharm 59:31-43
12. Ebdrup S, Petterson I, Rasmussen HB, Deussen HJ, Frost JA, Mortensen SB, Fleckner J, Pridal L, Nygaard L, Sauerberg P (2003) Synthesis and biological and structural characterization of the dual acting peroxisome proliferator- activated receptor a/c agonist Ragaglitazar. J Med Chem 46:1306-1317 (Pubitemid 36512696)
13. Fagerberg B, Edwards S, Halmos T, Lopatynski J, Schuster H (2005) Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia 48:1716-1725 (Pubitemid 41317824)
14. Furusjö E, Svenson A, Rahmberg M, Andersson M (2006) The importance of outlier detection and training set selection for reliable environmental QSAR predictions. Chemosphere 63: 99-108
15. Hall LH, Mohney BK, Kier LB (1991) The electrotopological state: an atom index for QSAR. Quant Struct Act Relat 10:43-51
16. Hanch C, Muir RM, Fujita T, Maloney P, Geiger E, Streich M (1963) Correlation of biological activity of plant growth regulators and chloromycetin derivatives with Hammett constants and partition coefficient. J Am Chem Soc 85:2817-2824
17. Hawkins DM, Basak SC, Mills D (2003) Assessing model fit by crossvalidation. J Chem Inf Comput Sci 43:579-586
18. Hendrickson MA, Nicklaus MC, Milne GWA, Zaharevitz D (1993) D.CONCORD and CAMBRIDGE: comparison of computergenerated chemical structures with X-ray crystallographic data. J Chem Inf Comput Sci 33:155
19. Henke BR (2004) Peroxisome proliferators-activated receptor a/c dual agonists for the treatment of type 2 diabetes. J Med Chem 47:4118-4127 (Pubitemid 39045415)
20. Karelson M (2000) Molecular descriptors in QSAR/QSPR. Wiley Interscience, New York, pp 220-221
21. Kordik CP, Reitz AB (1999) Pharmacological treatment of obesity: therapeutic strategies. J Med Chem 42:181-201 (Pubitemid 29069852)
22. Kovatcheva A, Buchbauer G, Golbraikh A, Wolschann P (2003) QSAR modeling of r-campholenic derivatives with sandalwood odor. J Chem Inf Comput Sci 43:259-266
23. Lin Y, Sun Z (2010) Current views on type 2 diabetes. J Endocrinol 204:1-11. doi:10.1677/JOE-09-0260
24. Lin Q, Ruuska SE, Shaw NS, Dong D, Noy N (1999) Ligand selectivity of the peroxisome proliferator-activated receptor a. Biochemistry 38:185-190 (Pubitemid 29035685)
25. Liu K, Xu L, Berger JP, MacNaul KL, Zhou G, Doebber TWM, Forrest J (2005) Discovery of a novel series of peroxisome proliferator-activated receptor a/c dual agonists for the treatment of type 2 diabetes and dyslipidemia. J Med Chem 48:2262-2265 (Pubitemid 40516418)
26. Luco JM, Ferretti FH (1997) QSAR based on multiple linear regression and partial least square methods for the anti-HIV activity of a large group of HEPT derivatives. J Chem Inf Comput Sci 37:392-401 (Pubitemid 127603544)
27. Markt P, Schuster D, Kirchmair J, Laggner C, Langer T (2007) Pharmacophore modeling and parallel screening for PPAR ligands. J Comput Aided Mol Des 21:575-590. doi:10.1007/s10822-007-9140-0 (Pubitemid 350238548)
28. Mudaliar S, Hery RR (2002) PPAR agonists in health and disease: pathophysiologic and clinical overview. Curr Opin Endocrinol Diabetes 9:285-302 (Pubitemid 36092158)
29. Paliwal S, Narayan A, Paliwal S (2009) Quantitative structure activity relationship analysis of dicationic diphenylisoxazole as potent anti-trypanosomal agents. QSAR Comb Sci 28:1367-1375
30. Paliwal SK, Pal M, Siddiqui AA (2010a) Quantitative structure activity relationship analysis of angiotensin II AT1 receptor antagonist. Med Chem Res 19:475-489
31. Paliwal SK, Singh S, Kumari S, Siddiqui AA, Paliwal SK (2010b) QSAR studies of imidazo [1,5a]quinoxalines amides, carbamates and urea as potent GABA modulators. Indian J Chem B 49B: 554-560
32. Paliwal SK, Das S, Yadav D, Saxena M, Paliwal SK (2010c) Quantitative structure activity relationship (QSAR) of N6-substituted adenosine receptor agonists as potential antihypertensive agents. Med Chem Res. doi:10.1007/s00044-010-9478-z
33. Paliwal S, Seth D, Yadav D, Paliwal S, Yadav R (2011) Development of a robust QSAR model to predict the affinity of pyrrolidine analogs for dipeptidyl peptidase IV (DPP-IV). J Enzym Inhib 26:129-140. doi:10.3109/14756361003777057
34. Prasad YR, Kumar PR, Smiles DJ, Babu PA (2008) QSAR studies on chalcone derivatives as antibacterial agents against Bacillus pumilis. Arkivoc 11:266-276
35. Rameshwar N, Krishna K, Kumar BA, Parthasarathy T (2006) QSAR studies of N 1-(5-chloro-2-pyridyl)-2-{[4-(alkylmethyl)benzoyl] amino}-5-chlorobenzamide analogs. Bioorg Med Chem 14: 319-325 (Pubitemid 41767591)
36. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM (1999) PPARc is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4:611-617. doi:10.1016/S1097-2765(00) 80211-7 (Pubitemid 29531140)
37. Rudolph J, Chen L, Majumdar D, Bullock WH, Burns M, Claus T, Dela Cruz FE, Daly M, Ehrgott FJ, Johnson JS, Livingston JN, Schoenleber RW, Shapiro J, Yang L, Tsutsumi M, Ma X (2007) Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR a/d/c pan agonists: synthesis, structure-activity relationship, and in vivo efficacy. J Med Chem 50:984-1000 (Pubitemid 46394001)
38. Sadowski J, Gasteiger J (1993) From atoms and bonds to threedimensional atomic coordinates: automatic model builders. Chem Rev 93:2567-2581
39. Takahashi M, Eto M, Makino I (1993) Peripheral insulin resistance precedes the onset of hyperglycemia in spontaneously diabetic Chinese hamsters of Asahikawa colony. Diabetes Res Clin Pract 20:101-109 (Pubitemid 23265101)
40. Tarko L, Ivanciuc O (2001) QSAR modeling of the anticonvulsant activity of phenylacetanilides with preclav (property evaluation by class variables). Match Commun Math Comput Chem 44:201-214 (Pubitemid 33592480)
41. Tenenbaum A, Motro M, Fisman EZ (2005) Dual and pan-peroxisome proliferators-activator receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 4:14
42. Todeschini R, Consonni V (2000) Handbook of molecular descriptors: methods and principles in medicinal chemistry. Wiley- VCH, Weinheim
43. Topliss JG (1993) Some observation on classical QSAR. Perspect Drug Discov Des 1:253-268
44. Wang M, Ross SA, Gulve EA (2004) Chemistry and biochemistry of type 2 diabetes. Chem Rev 104:1255-1282
45. Willson TM, Brown PJ, Sternbach DD, Henke BR (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43: 527-550 (Pubitemid 30127149)
46. Wold S (2001) PLS-regression: a basic tool of chemometrics. Chemom Intell Lab Syst 58:109-130 (Pubitemid 33033283)
47. Wylie WA, Vinter JG (1994) In: Gardner M (ed) Molecular modeling and drug design. Macmillan, London
48. Yanase T, Yashiro T, Takitani K, Kato S, Taniguchi S, Takayanagi R, Nawata H (1997) Differential expression of PPAR c1 and c2 isoforms in human adipose tissue. Biochem Biophys Res Commun 233:320-324. doi:10.1006/bbrc.1997. 6446 (Pubitemid 27226623)
49. Zoete V, Grosdidier A, Michielin O (2007) Peroxisome proliferatoractivated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta Mol Cell Biol Lipid 1771:915-925. doi:10.1016/j.bbalip.2007.01.007 (Pubitemid 47208545)